Rituximab Plus CellCept Durably Improves Lung Function in Refractory SSc-ILD, Study Suggests
Rituximab, in combination with CellCept (mycophenolate mofetil), reverses the decline in lung function in people with interstitial lung disease (ILD) associated with scleroderma (SSc) who did not respond to immunosuppressant therapies, a study suggested. The study, “…